Enzolytics Inc. (OTCMKTS: ENZC) has announced a rational protocol that it plans to excite to meet its objective of a therapeutic cure for HIV production and a planned protocol for addressing current and future epidemics. Notably, the company has defined the protocol following the collaboration with Intel Corporation in applying AI to expedite drug discoveries.
Enzolytic collaborates with Intel.
The company’s collaboration focuses on realizing groundbreaking drug development and discovery pathways. Most importantly, the collaboration will include exploring monoclonal antibodies’ interaction with viruses in 3-dimensional matrices. Therefore the alliance opens up new innovative drug development and discovery pathways.
In the same way, Enzolytics is partnering with Intel to research and bring effective medicines and treatments for current and novel viral infections, it is also actively pursuing other biotech alliances. The company proposes a collaboration to completely execute the following protocol for creating and deploying treatments to treat current and future pandemics, in combination with its patented and clinically tested anti-HIV peptide ITV-1.
Enzolytics advance ITV-1 anti-HIV therapeutics to clinical trials
Analytics has finalized definitive plans to take its ITV-1 anti-HIV therapeutic to clinical studies and distribution across Europe. Completing the steps will make the anti-HIV therapy a substantial revenue stream for Enzolytics, which is massive for both the company’s profitability and human health.
The company had earlier advanced the ITV-1 anti-HIV therapeutics toward approval under the Bulgarian Drug Agency. However, there was an interruption of the process before completion despite significant positive results being documented in the process. The positive results give Enzolytics confidence that the planned clinical under EMA will be successful.
Charles Cotropia, Enzolytics CEO, said that the company’s goal is offering a new, safer, and better HIV therapeutic. Currently, available treatment is mainly through lifelong use of ARVA that has expensive with long-lasting adverse effects.
 Advances Anti-HIV ITV-1 Therapeutic To Clinical Trials){kind=link}